Polypharmacy: a risk factor to consider in valproate‐induced hyperammonaemic encephalopathy

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|45|4|433-436

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.45, Iss.4, 2015-12, pp. : 433-436

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valproate: Hyperammonaemic encephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1429, 2012-01 ,pp. : 43-43

Adis International

Access to resources Recommend Favorite

Valproate: Reversible brain pseudoatrophy and hyperammonaemic encephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1266, 2009-01 ,pp. : 30-30

Adis International

Access to resources Recommend Favorite

Valproate-Induced Pancreatitis: Implications for Clinicians

By  

Child and Adolescent Psychopharmacology News, Vol. 7, Iss. 1, 2002-02 ,pp. : 6-9

Guilford Publications Inc

Access to resources Recommend Favorite

Carbamazepine/valproate: Hyperammonaemic encephalopathy and syndrome of inappropriate secretion of antiduretic hormone: case report

By  

Reactions Weekly, Vol. 1, Iss. 1411, 2012-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Fluorouracil: Hyperammonaemic encephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1418, 2012-01 ,pp. : 25-25

Adis International

Access to resources Recommend Favorite